N24 Experience with Ustekinumab (STELARA®) in Paediatric inflammatory bowel disease (pIBD) – A case series

• Published in: Journal of Crohn's and colitis 2019-01, Vol.13 (Supplement_1), p.S568-S568
• Main Authors: Buckingham, R, Sider, S, Cococcioni, L, ElZein, A, Chadokufa, S, Shah, N, Ocholi, A, Borrelli, O, Kiparissi, F
• Format: Article
• Language: English
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjy222.1012

Abstract Background Ustekinumab (UST) is a monoclonal antibody against IL 12/23 and is thought to drive inflammation in psoriasis and gastrointestinal inflammation. Two phase 2b studies have shown that UST induces and maintains clinical response in Crohn's disease (CD). Data of the effectiveness of UST in pIBD are lacking. Methods The aim of the study was to evaluate effectiveness and safety of UST as a treatment for pIBD after failure of anti-TNFa and Vedolizumab. Methods Retrospective study of demographic characteristics, medical history, dosage and schedule of UST administration, as well as data on pre and post ESR, calprotectin and PCDAI. Results A total of 5 patients on UST were identified, age range 8–15 years, median 12 years, age at diagnosis 2–10 years, median 5 years, 3 males. Crohns n = 4 and UC n = 1, followed up for up to 15 months following initiation of treatment. All 5 patients had previously failed at least two biologic treatments. All 5 patients received UST 8 weekly at IV – Single, initial dose of 6 mg/kg, as intravenous infusion over at least 60 min. SC – Subsequent doses. The first subcutaneous dose of 90 mg if >40 kg and 45 mg < 40 kg. In 4/5 patients UST significantly reduced ESR, 4/5 significantly reduced calprotectin and all improved PCDAI and PGA scores. https://planner.smart-abstract.com/ecco2019/submission/en/abstract/13317/content# Start date Pre ESR Post ESR Pre Calprotectin Post Calprotectin Pre PCDAI Post PCDAI March 2018 No data 17 >1800 915 10 June 2018 46 23 4817 1960 55 5 September 2018 15 12 1525 Pending 25 20 August 2017 19 8 5309 2023 40 20 June 2018 90 10 156 38 45 5 Conclusions Ustekinumab seems to be effective and safe treatment in pIBD patients with no reported adverse events. We suggest multi-centre prospective Paediatric studies to advance knowledge and improve patient outcomes.